Lars Fruergaard Jørgensen, CEO of Novo Nordisk, speaks during an interview in New York on Aug. 10, 2022.
Novo Nordisk 's top executive is slated to face a Senate grilling on Tuesday over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both injections soars in the U.S.Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate Health, Education, Labor and Pensions Committee hearing at 10 a.m.
It comes roughly five months after Sen. Bernie Sanders, the Vermont independent who chairs the Senate panel, opened an investigation into the Danish drugmaker's pricing practices.
Sanders contends that Novo Nordisk charges Americans substantially higher prices for its blockbuster drugs than it does for patients in other countries.
Before insurance, Ozempic costs nearly $969 per month and Wegovy costs almost $1,350 per month in the U.S.
Persons:
Lars Fruergaard Jørgensen, Sen, Bernie Sanders, Sanders
Organizations:
Novo Nordisk, Health, Education, Labor, Washington , D.C, Nordisk
Locations:
New York, U.S, Washington ,, Vermont, Danish, Germany